Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
C. Pelaia (Catanzaro (CZ), Italy), N. Lombardo (Catanzaro (CZ), Italy), M. Busceti (Catanzaro (CZ), Italy), A. Dragone (Catanzaro (CZ), Italy), G. Piazzetta (Catanzaro (CZ), Italy), C. Crimi (Catania (CT), Italy), A. Vatrella (Salerno (SA), Italy), G. Pelaia (Catanzaro (CZ), Italy). Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis. 893

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Intranasal budesonide improves quality of life in patient with COPD and chronic nasal symptoms Source: International Congress 2016 – COPD diagnosis and management Year: 2016